A detailed history of Price T Rowe Associates Inc transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Price T Rowe Associates Inc holds 920,086 shares of ACAD stock, worth $13.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
920,086
Previous 3,999,550 77.0%
Holding current value
$13.6 Million
Previous $74 Million 79.78%
% of portfolio
0.0%
Previous 0.01%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$14.62 - $18.42 $45 Million - $56.7 Million
-3,079,464 Reduced 77.0%
920,086 $15 Million
Q1 2024

May 15, 2024

SELL
$17.79 - $30.86 $21 Million - $36.4 Million
-1,178,959 Reduced 22.77%
3,999,550 $74 Million
Q4 2023

Feb 14, 2024

SELL
$20.78 - $31.77 $1.07 Million - $1.64 Million
-51,652 Reduced 0.99%
5,178,509 $162 Million
Q3 2023

Nov 14, 2023

SELL
$20.84 - $33.47 $16.3 Million - $26.2 Million
-783,753 Reduced 13.03%
5,230,161 $109 Million
Q2 2023

Aug 14, 2023

BUY
$17.8 - $25.65 $26 Million - $37.5 Million
1,463,008 Added 32.15%
6,013,914 $144 Million
Q1 2023

May 15, 2023

BUY
$16.32 - $20.92 $4.43 Million - $5.68 Million
271,652 Added 6.35%
4,550,906 $85.6 Million
Q4 2022

Feb 14, 2023

SELL
$14.2 - $18.63 $8.69 Million - $11.4 Million
-612,094 Reduced 12.51%
4,279,254 $68.1 Million
Q3 2022

Nov 14, 2022

BUY
$14.11 - $18.27 $2.79 Million - $3.61 Million
197,633 Added 4.21%
4,891,348 $80 Million
Q2 2022

Aug 15, 2022

SELL
$13.01 - $27.22 $3.71 Million - $7.76 Million
-285,221 Reduced 5.73%
4,693,715 $66.1 Million
Q1 2022

May 16, 2022

SELL
$20.94 - $27.5 $94.4 Million - $124 Million
-4,507,325 Reduced 47.51%
4,978,936 $121 Million
Q4 2021

Feb 14, 2022

BUY
$16.79 - $27.09 $901,908 - $1.46 Million
53,717 Added 0.57%
9,486,261 $221 Million
Q3 2021

Nov 15, 2021

SELL
$15.78 - $24.77 $12.1 Million - $19 Million
-766,287 Reduced 7.51%
9,432,544 $157 Million
Q2 2021

Aug 16, 2021

BUY
$19.4 - $27.42 $35.8 Million - $50.6 Million
1,844,820 Added 22.08%
10,198,831 $249 Million
Q1 2021

May 17, 2021

BUY
$25.02 - $54.99 $11.9 Million - $26.2 Million
476,186 Added 6.04%
8,354,011 $216 Million
Q4 2020

Feb 16, 2021

BUY
$41.04 - $56.79 $323 Million - $447 Million
7,877,825 New
7,877,825 $421 Million

Others Institutions Holding ACAD

About ACADIA PHARMACEUTICALS INC


  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.39B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.